Skip to Content

Meet Our Partners

We secure partners who are working towards our mutual goal of finding a treatment or cure for hypoPARAthyroidism. We also partner with organizations that can help us educate both patients and physicians about our disease. Finally, we partner with organizations that can help us help patients with navigating insurance, disability, and other treatment needs.

Calcilytix logo

Calcilytix

Calcilytix Therapeutics is a clinical-stage biopharmaceutical company based in California, USA. We are an affiliate of BridgeBio Pharma, whose goal is to create life-altering medicines that target well-characterized genetic diseases at their source.

Calcilytix is investigating Encaleret as a potential treatment for ADH1 (autosomal dominant hypocalcemia type 1), a genetic cause of hypoPARAthyroidism. Encaleret is an investigational, orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, with the goal of normalizing serum calcium and lowering urine calcium. Encaleret is not yet approved by the FDA or any other regulatory authority to treat ADH1.

Together with physicians and the community, the Calcilytix team aims to develop an effective treatment option for people living with ADH1, the most common genetic form of isolated hypoPARA.

To learn more about our company and ongoing clinical studies, please visit www.bridgebio.com. Also, be sure to check out www.calcilytix.com and www.detecthypopara.com.

ACCESS OUR FREE GENETIC TESTING KITS 


Clinical Trials

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE)

CLARIFY: ADH1 and ADH2 Disease Monitoring Study (DMS)

Ascendis Pharma logo

Ascendis Pharma

Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science, and passion, we use our TransCon® technology platform to create new and potentially best-in-class therapies.

Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. Ascendis is headquartered in Copenhagen, Denmark, and has additional offices in Heidelberg, Munich, and Berlin in Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey in the United States. 

For more information about Ascendis, please visit us at ascendispharma.us or follow Ascendis on Twitter and LinkedIn.

Visit LivingHypoPara.com to learn more about hypoPARAthyroidism and to gain access to our library of lifestyle tips and wellness resources.

Information regarding the EAP (early access program) EAP Patient Info

Information for physicians to apply for EAP EAP Physician Info

 


 

Amolyt Pharma logo

Amolyt Pharma

We are building and advancing a portfolio of innovative therapies through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. Currently, our development pipeline includes two therapeutic peptide programs: eneboparatide for the treatment of hypoPARAthyroidism and AZP-3813 for the treatment of acromegaly. We also continuously look for external innovation in rare endocrine and related diseases.

Our global management team is composed of a highly dedicated group of senior executives with proven drug development, registration and commercialization, and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and related disease.

We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.

Please visit our website at amolytpharma.com and our page dedicated to patients amolytpharma.com/patients.


Clinical Trials

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic HypoPARAthyroidism (CALYPSO)

Global Genes

Global Genes is a 501(c)(3) non-profit organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally.

Global Genes’ story began with our loved ones. We are the friends, family and supporters of patients close to us who are affected by rare disease. We understand the confusion, the overwhelming experience of the unknown and the feelings of isolation all too well. And we know we aren’t alone. That’s the reason Global Genes was born – to connect, empower and inspire the rare disease community.

Provide patient advocates with a continuum of services to accelerate their path from early support and awareness through research readiness, using a collaborative approach that involves biopharma, researchers and funders, with data as a central core.

We are also apart of the Global Genes Global Advocacy Alliance 

Follow Global Genes on FacebookInstagramYouTube and Twitter

MBX Biosciences logo

MBX Biosciences

MBX Biosciences is pioneering Precision Endocrine Peptide™ (PEP™) therapeutics to help people with endocrine disorders live fuller and healthier lives. Our mission is to restore health, simplify management and enable greater access for patients with endocrine diseases. The company’s lead product candidate for the treatment of hypoPARAthyroidism is currently in development and is designed to restore PTH physiology and correct the mineral imbalances to alleviate symptoms of the disorder. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow on LinkedIn and Twitter.

Contact MBX Biosciences here or at [email protected]

NORD

NORD (National Organization for Rare Diseases) advances practical, meaningful, and enduring change so people with rare diseases can live their fullest and best lives. Every day, we elevate care, advance research, and drive policy in a purposeful and holistic manner to lift up the rare disease community.
Follow NORD on FacebookInstagramLinkedInTwitter and YouTube

Or contact NORD here

Rare Revolution

Rare Revolution Magazine is working to bring about a dramatic and wide reaching change in conditions and attitudes for the rare disease community.

Check out their website here

Follow them on LinkedInFacebookInstagram and Twitter

Takeda logo

Takeda Pharmaceutical Company

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.

Our corporate philosophy tells the story of Takeda — who we are, what we do, how we do it, and why it matters. It reminds us how together, we can achieve “better health for people, brighter future for the world”.

We connect to our history and Japanese heritage through everything we do today, to bring our purpose, values, vision, and imperatives to life.

Learn more about the NATPARA Special Use Program.

Read the latest news on the NATPARA recall.